NCT06678724 Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
| NCT ID | NCT06678724 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Head and Neck Cancers- Squamous Cell |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2025-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the prognostic value of circulation tumor emboli (CTM) in recurrent/metastatic head and neck cancer patients and also the changes of tumor microenvironment by different treatment modalities and drugs. The main questions it aims to answer are: 1. Investigators plan to correlate circulating tumor cells (CTC), circulating tumor emboli (CTM), and the composition of NK cells in CTM with clinical outcomes and establish their association with patient prognosis. 2. Investigators plan to understand the composition of NK cells and the immune cell components within CTM, and correlate these findings with treatment efficacy. Patients with recurrent/metastatic head and neck cancer will be included after informed consent and investigators will collect blood samples for analysis from them under the treatment provided by their primary care physicians.
Eligibility Criteria
Inclusion Criteria: must fulfill with all the items below * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2. * \>=20 years old. * had pathologically confirmed squamous cell carcinoma of the oropharynx, oral cavity, hypopharynx, or larynx that was recurrent or metastatic and not curable by local therapy. * had at least one tumor lesion measurable per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Medical records during treatment are available. Exclusion Criteria: * Medical records during treatment unavailable * Could not cooperate with blood sampling * Without informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06678724 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Head and Neck Cancers- Squamous Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06678724 currently recruiting?
Yes, NCT06678724 is actively recruiting participants. Contact the research team at G04187@hch.gov.tw for enrollment information.
Where is the NCT06678724 trial being conducted?
This trial is being conducted at Zhubei, Taiwan.
Who is sponsoring the NCT06678724 clinical trial?
NCT06678724 is sponsored by National Taiwan University Hospital. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.